Evidence map›Paper›PMID 41533312›Full record

ArticleJapanese journal of radiology2026

Quantitative indices from post-PRRT SPECT/CT: an exploratory approach to early imaging biomarkers in neuroendocrine tumors.

Takanori Bando, Hideki Otsuka, Tamaki Otani, Ryosuke Kasai, Yoichi Otomi, Sana Nagao, Shota Azane, Satoru Takashi, Yamato Kunikane, Masafumi Amano and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takanori BandoDepartment of Radiological Technology, Tokushima University Hospital, Tokushima, Japan.
Hideki OtsukaDepartment of Medical Imaging/Nuclear Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. hideki.otsuka@tokushima-u.ac.jp.ORCID http://orcid.org/0000-0001-7165-6099
Tamaki OtaniAdvance Radiation Research, Education and Management Center, Tokushima University, Tokushima, Japan.
Ryosuke KasaiDepartment of Medical Imaging/Nuclear Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Yoichi OtomiDepartment of Radiology and Radiation Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Sana NagaoDepartment of Radiation Technology, Kawashima Hospital, Tokushima, Japan.
Shota AzaneDepartment of Radiological Technology, Tokushima University Hospital, Tokushima, Japan.
Satoru TakashiDepartment of Radiological Technology, Tokushima University Hospital, Tokushima, Japan.
Yamato KunikaneDepartment of Radiological Technology, Tokushima University Hospital, Tokushima, Japan.
Masafumi AmanoDepartment of Radiological Technology, Tokushima University Hospital, Tokushima, Japan.
Yasuyuki OkadaDepartment of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Tetsuji TakayamaDepartment of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Takashi KawanakaDepartment of Radiology and Radiation Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Hitoshi IkushimaDepartment of Therapeutic Radiology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Masafumi HaradaDepartment of Radiology and Radiation Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess therapeutic response in patients with neuroendocrine tumors (NETs) using quantitative post-therapy MATERIALS AND

methodsIn this retrospective study, we analyzed 31 lesions in 7 patients with NETs treated with four cycles of peptide receptor radionuclide therapy (PRRT) with

resultsSUVmax and SUVpeak correlated strongly with K-S and were consistent across thresholding methods. MTV and TLuU varied by VOI definition, but the cutoff method produced more stable longitudinal assessments. Lesions with early SUV-based RR reductions at the second PRRT cycle showed continued decline across treatment. Patients were categorized as "Good Responder," "Responder," or "Non-responder" based on quantitative trends, which aligned with visual assessments and CT findings.

conclusionQuantitative post-PRRT SPECT/CT provides objective, reproducible metrics for assessing NET therapy response. A fixed SUV cutoff allows standardized volumetric assessment. Early SUV-based index declines may act as predictive biomarkers of treatment efficacy, supporting personalized theranostic strategies.

Indexed as

Neuroendocrine TumorsOctreotideOrganometallic CompoundsSingle Photon Emission Computed Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle AgedRadiopharmaceuticalsReceptors, PeptideRetrospective StudiesTreatment OutcomeTumor Burdenlutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, Peptide177Lu-DOTATATENeuroendocrine tumors (NETs)Peptide receptor radionuclide therapy (PRRT)Quantitative indicesStandardized uptake value (SUV)Theranostics

Identifiers

PMID41533312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.